Akero

Akero Therapeutics specializes in developing innovative therapies targeting metabolic dysfunction-associated steatohepatitis (MASH), with its flagship investigational drug, efruxifermin (EFX), positioned as a potentially best-in-class treatment. The company’s platform is distinguished by the integration of advanced clinical trial methodologies and the use of AI-powered digital pathology, allowing for precise, quantitative assessment of liver fibrosis and treatment efficacy. Akero’s ongoing clinical studies span multiple late-stage trials in various stages of MASH, including both pre-cirrhotic and cirrhotic patient populations. The company’s science-driven approach addresses not only liver histology improvements but also broader metabolic regulation, promising benefits for overall metabolic health. With cutting-edge research infrastructure and a robust clinical pipeline, Akero aims to deliver transformative outcomes for patients affected by complex metabolic and liver diseases.